Project Grant R43AG076342

Award Date 9/30/21
Completion Date 8/31/23
Dollars Obligated $1.4M
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Newtonville, MA 02458, USA
Similar Awards
This federal Cooperative Agreement award from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) provides $1,778,991 to establish a federated digital pathology platform for Alzheimer's disease and related dementias (AD/ADRD) research and diagnostics. The University of Kentucky Research Foundation, as the prime awardee, will develop an open-source platform to aggregate and curate digital neuropathology slide data across multiple repositories, enabling...
The National Institute on Aging (NIA), under the Aging Research federal grant program (CFDA 93.866), awarded Neucyte Inc. a $500,000 Project Grant to develop an Alzheimer's disease (AD) and AD-related dementia (ADRD) microphysiological systems (MPS) platform using nanoluciferase-based technology. The goal is to create a scalable, reproducible "mini-brain" assembloid model using human induced pluripotent stem cells to facilitate high-throughput screening of potential AD/ADRD...
This federal Project Grant award from the National Institute on Aging (NIA), under the Aging Research program (CFDA 93.866), is funding the development of a perivascular space (PVS) mapping toolset as a diagnostic aid for Alzheimer's disease (AD). The award of $1,193,370 will support Neuroscope Inc., a woman-owned small business located in Scarsdale, NY, in building the necessary IT infrastructure and obtaining FDA 510(k) approval to commercialize their PVS mapping technologies. These...
The National Institute on Aging (NIA) awarded a $1,931,965 Project Grant (CFDA 93.866 - Aging Research) to the Regenerative Research Foundation to develop and validate a novel human induced pluripotent stem cell (iPSC) model that incorporates cerebral cortical neurons, vascular endothelial cells, and other cell types to study cerebrovascular interactions in Alzheimer's disease-related dementias (ADRD). The R61 phase of the project will focus on optimizing the integration of the Foundation's...
This $500,000 Project Grant awarded by the National Institute on Aging (CFDA 93.866 Aging Research) will support Sxrna Technologies, Inc. in developing an organoid toolkit for Alzheimer's disease (AD) and Alzheimer's-disease-related dementias (ADRD). The company aims to create a platform for identifying senescent cells in living tissue, which can provide insights into the aging process and enable high-throughput drug screening in complex 3D tissue models. Specifically, the grant will fund...
This $1,785,580 Project Grant awarded by the National Institute on Aging (CFDA 93.866 - Aging Research) to The Trustees of the University of Pennsylvania aims to develop a novel spatial multi-omics technology and apply it to comprehensively map cellular states and microenvironments in the human hippocampus in the context of Alzheimer's disease. The key products and services to be delivered under this 5-year grant include: Development of a first-of-its-kind technology for spatially...
This $4.49 million project grant from the National Institutes of Health's National Institute on Aging will fund research at The Washington University to investigate the relationship between amyloid plaque deposition, cellular metabolic dysfunction, and functional brain organization in Alzheimer's disease (AD) mice models. Over three years, the researchers will use multi-photon fluorescence lifetime imaging microscopy, multi-parametric photoacoustic microscopy, and wide-field optical imaging...
This $9,631,026 Project Grant awarded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) will support research at Northwestern University to investigate the impact of atherosclerosis on the brain's microvasculature and the associated relationship with Alzheimer's disease (AD) pathology. The comprehensive research project aims to analyze the structural, molecular, and...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will develop advanced diffusion MRI technology to enable high-resolution, high-fidelity imaging of the medial temporal lobe in Alzheimer's disease (AD). The $851,700 award, spanning from May 2024 to February 2026, will be used by the awardee, The General Hospital Corporation (doing business as Massachusetts General Hospital), to create a distortion-free, motion-corrected diffusion MRI acquisition...
This $2,236,336 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to develop a new microscopy tool called "Multiplexed Ultrastructure Expansion Microscopy" (Multiplex-UMEXM) to study lipid accumulation and organelle changes in Alzheimer's disease (AD). The key products to be delivered are: Optimizing and validating Multiplex-UMEXM for lipid preservation, molecular staining, and nanoscale imaging in both mouse and human brain tissue...

AN AUTOMATED PLATFORM FOR 3D RECONSTRUCTION AND PROFILING OF POST-MORTEM ALZHEIMER'S DISEASE BRAINS - PROJECT SUMMARY AD IS A COMPLEX, PROGRESSIVE NEURODEGENERATIVE DISEASE AND IS THE MOST COMMON CAUSE OF DEMENTIA AMONG THE ELDERLY. IT HAS A CLEAR SPATIAL AND TEMPORAL PROGRESSION; MULTIPLE LINES OF EVIDENCE SHOW THAT THE DEGENERATION PATTERNS SEEN IN AD ARE NOT RANDOM BUT SHOW A CHARACTERISTIC ANATOMICAL SEQUENCE AS THE PATHOLOGY ADVANCES OVER DECADES. THE MECHANISMS THAT CAUSE THESE SPATIAL PATTERNS ARE POORLY UNDERSTOOD AND BASIC QUESTIONS ABOUT THE RELATIVE CONTRIBUTIONS OF MICROSCOPIC MOLECULAR MECHANISMS VERSUS MACROSCOPIC ANATOMICAL CHANGES IN DRIVING AD PROGRESSION REMAIN UNCLEAR. UNFORTUNATELY, WHOLE BRAIN TECHNIQUES LIKE MRI LACKS THE NECESSARY MOLECULAR CONTRAST AND RESOLUTION TO ANSWER THESE QUESTIONS. HISTOLOGY CAN REVEAL THE MICROSCOPIC, MOLECULAR SIGNATURES, BUT IS CONSTRAINED TO SMALL 2D SECTIONS DUE TO TECHNICAL LIMITATIONS WITH LARGE SCALE HISTOLOGY, PARTICULARLY 3D HISTOLOGY. THESE LIMITATIONS MAKE IT DIFFICULT TO MAP AD PROGRESSION AND LIMIT THE USEFULNESS OF POST-MORTEM TISSUE THAT MIGHT REVEAL CRUCIAL CLUES ABOUT AD. IN THIS PROPOSAL WE WILL ADDRESS THIS BARRIER BY PROVIDING A FEE-FOR-SERVICE SECTIONING, SLICE MOUNTING, STAINING, AND IMAGING PLATFORM THAT WILL OFFER NON-SPECIALIZED LABS THE ABILITY TO OBTAIN HIGH QUALITY 3D SERIAL SECTION RECONSTRUCTIONS OF POST-MORTEM HUMAN BRAINS UP TO ENTIRE HEMISPHERES. SPECIMENS CAN BE SENT TO TISSUEVISION WHERE THEY WILL BE SECTIONED AT THICKNESSES RANGING FROM 50 MICRONS TO 2 MM, WITH ALTERNATING BLOCK FACE IMAGING BETWEEN SECTIONS TO HELP FACILITATE 3D RECONSTRUCTION. EACH MOUNTED SECTION IS AVAILABLE FOR FURTHER STAINING AND DIGITIZATION AT HIGH RESOLUTION WITH WHOLE SLIDE IMAGING (WSI) AND SERVED OVER THE CLOUD TO THE CLIENT WITH OPTIONAL 3D MODELING. THE PHYSICAL SECTIONS CAN BE RETURNED TO THE CLIENT OR STORED FOR FURTHER FOLLOW-UP ANALYSES. THIS PROPOSAL COMBINES EXPERTISE IN MICROSCOPY AND 3D HISTOLOGY AT TISSUEVISION WITH WORLD- CLASS CLINICAL RESEARCHERS AT INDIANA UNIVERSITY AND BUILDS ON EXISTING WORK AT TISSUEVISION. THE SECTION CAPTURE AND SLIDE MOUNTING IS BASED ON EXISTING TECHNOLOGY CONTAINED WITHIN OUR TISSUECYTE 1600FC STPT PLATFORM FOR MOUSE AND RAT BRAINS. WE ALSO BUILD ON A STRONG COLLABORATION WITH JACKSON LABS AND THE MODEL-AD CENTER WITH AN EXISTING TISSUEVISION PHASE II NIA SBIR TO MAP AD SPATIAL PROGRESSION IN MOUSE MODEL BRAINS. WE WILL EXTEND THE COLLABORATION TO CLINICAL COLLABORATORS AT THE MODEL-AD AT INDIANA UNIVERSITY WHO WILL BE SUPPLYING POST-MORTEM HUMAN TISSUE AND PROVIDING GUIDANCE AND FEEDBACK ON THE HISTOLOGICAL QUALITY. WHILE OUR FOCUS IS ON AD IN THIS PROJECT, THE PROPOSED TECHNOLOGY WILL HAVE BROAD IMPACT ACROSS A WIDE RANGE OF DISCIPLINES, FROM CARDIAC BIOLOGY, INFECTIOUS DISEASES, CANCER, AND BASIC RESEARCH.

Posted 9/21/21, 12:00 AM